What does the UK’s pro-innovation approach to AI mean for life sciences companies?

It remains to be seen whether AI developers in the medical sector will benefit from the UK’s ‘flexible’ regulatory environment or find the lack of cohesion detrimental, say Jackie Mulryne and Beatriz San Martin of Arnold & Porter.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

UPC appeals court upholds Abbott injunction in glucose monitoring patent dispute

30 March 2026 Judges found no reason to set aside provisional measures issued by a local division, following a challenge from Sinocare and A Menarini Diagnostics.

Europe

WIPR debuts Global In-House Elite 2026

26 March 2026 LSIPR sister title launches vetted list celebrating leading in-house counsel who demonstrate exceptional ability in managing their organisation's IP portfolio, legal team, and IP culture.

Europe

UK court deals blow to Spanish pharma’s SPC bid for contraceptive

24 March 2026 The drugmaker’s attempt to extend protection for a fast-growing oestrogen-free contraceptive ran into a landmark EU ruling, with the court not persuaded to read it narrowly.

More features

UPC appeals court upholds Abbott injunction in glucose monitoring patent dispute

Novartis bets $2bn on biologics as Xolair patents fade

WIPR debuts Global In-House Elite 2026

mRNA litigation: Who’s winning, who’s filing, and what’s next

Dechert boosts litigation bench with partner duo

UK court deals blow to Spanish pharma’s SPC bid for contraceptive

EPO reports record patent filings, but pharma and biotech lag

Part II: The race to replace semaglutide heats up

What does the UK’s pro-innovation approach to AI mean for life sciences companies?

More on this story

Editor's picks

Editor's picks

More features